Brief: FDA Expands U.S. Age Indication For EVO ICL
17/02/2026 21:27
Feb 17 (Reuters) - STAAR Surgical Co STAA.O: FDA EXPANDS U.S. AGE INDICATION FOR EVO ICL AS LONG-TERM SAFETY DATA REINFORCES MARKET SHIFT AWAY FROM LASER VISION CORRECTION STAAR SURGICAL CO - FDA EXTENDS EVO ICL USE TO PATIENTS 21-60 YEARS OLD Source text: ID:nBw1pM85Va Further company coverage: STAA.O ((Reuters.Briefs@thomsonreuters.com;))